Play Earnings CallPlay Earnings Call
Supernus Pharmaceuticals, Inc. (SUPN) BofA Securities CNS Therapeutics Virtual Conference 2025 December 8, 2025 10:45 AM EST
Company Participants
Jack Khattar – Founder, President, CEO, Secretary & Director
Conference Call Participants
Pavan Patel – BofA Securities, Research Division
Presentation
Unknown Attendee
Ladies and gentlemen, the program is about to begin. At this time, it is my pleasure to turn the program over to your host, Pavan Patel.
Pavan Patel
BofA Securities, Research Division
Great. Thanks. I’ll just give a quick introduction, given this is my first time hosting Supernus since I initiated coverage on October 29. I’ve been working for Jason Gerberry at Bank of America for close to 5 years now, focused on companies like Jazz, Horizon Therapeutics, Teva, Tarsus and United Therapeutics, just to name a few. And I chose Supernus as my first company to cover as lead analyst because I think it’s a company that’s undergone an impressive transformation to being a diversified CNS growth company. And I think Jack is a solid operator with a strong track record.
With that, I’m joined by Jack Khattar, who is the Founder and CEO of Supernus Pharmaceuticals, and he started this company as a spinout of Shire back in 2005, so 20-year anniversary and turned it into an up to $3 billion enterprise value company and so we can get straight into the Q&A.
Question-and-Answer Session
Pavan Patel
BofA Securities, Research Division
So the company most recently did BD deal for the acquisition of Sage. And now that we’re a full quarter into the Sage integration, can you provide some more granularity on the realization of the $200 million in annualized synergies? And are these savings coming mostly from SG&A? And have you done the work in order to go through the R&D programs and figure out what’s going to be eliminated
